Aequus Pharmaceuticals Inc. announced plans to advance its transdermal patch for pregnancy-related anti-nausea, AQS1303, following positive results from the proof of concept study completed in 2017. The Company will work with its regulatory and strategic consulting partner, Camargo Pharmaceutical Services, LLC ("Camargo"), to prepare for a pre-Investigational New Drug Application ("pre-IND") meeting with the US Food and Drug Administration ("FDA") to define the clinical strategy for approval in the United States. The Company anticipates pursuing an abbreviated 505(b)(2) pathway.